Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock

0
165

Shares of biotechnology company Revolution Medicines (NASDAQ: RVMD) have surged more than 134% so far this year. Billionaire investor Stanley Druckenmiller’s Duquesne Family Office drew attention to the stock by buying 316,000 shares of Revolution in the first quarter. The move has paid off for Druckenmiller, as the stock is up more than 105% since his purchase.

Revolution is a clinical-stage company that focuses on targeted therapies against RAS proteins to replace traditional chemotherapy in treating aggressive malignancies, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. The scientific community had regarded RAS proteins as undruggable because potential therapeutic agents struggled to bind their surfaces. However, Revolution successfully created druggable sites through its tricomplex inhibitor platform, thereby blocking cancer…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here